TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
News|Articles|January 25, 2023
Daily Dose: Semaglutide 2.4 mg and Long-term Weight Loss
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On January 24, 2023, we reported on a study published in Obesity that evaluated the effect of once-weekly semaglutide 2.4 mg on 2-year control of eating.
The study
Researchers tapped 2 years of treatment data with semaglutide 2.4 mg from the pivotal phase 3 STEP 5 clinical trial. STEP 5 compared semaglutide with placebo for long-term treatment of obesity or overweight in persons with at least 1 weight-related comorbidity and without diabetes. A total of 304 participants were enrolled and randomized to receive active drug or placebo and all received the same lifestyle intervention. For the current study, investigators evaluated STEP 5 data from a 19-item version of the Control of Eating Questionnaire (CoEQ) administered to a subgroup of trial participants at weeks 0, 20, 52, and 104.
Improvements in craving domain scores were positively correlated with reductions in body weight from baseline to week 104 in participants treated with semaglutide 2.4 mg. Scores for desire to eat salty and spicy food, cravings for dairy and starchy foods, difficulty in resisting cravings, and control of eating were significantly reduced with semaglutide versus placebo (P for all<.05).
Clinical implications
"The availability of semaglutide 2.4 mg represents an effective longer-term treatment for overweight or obesity by improving the control of eating and food cravings, which enables patients to achieve and maintain substantial weight loss."
Click here for more details.
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
3
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
4
JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS
5